Please try another search
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
James G. McArthur | 61 | 2021 | President, CEO, Treasurer, Secretary & Director |
Laurie Bartlett Keating | 69 | 2021 | Independent Chair of the Board |
Habib Joseph Dable | 54 | 2022 | Independent Director |
Heidi Henson | 57 | 2021 | Independent Director |
John Watts | - | - | Scientific Advisory Board Member |
Christopher Philip Ashton | 61 | 2019 | Independent Director |
Matthew Wood | - | - | Scientific Advisory Board Member |
John W. Day | - | 2021 | Scientific Advisory Board Member |
Charles Thornton | - | - | Scientific Advisory Board Member |
Beth McNally | - | - | Scientific Advisory Board Member |
Michael Gait | - | - | Founder & Scientific Advisory Board Member |
Brenda Wong | - | - | Scientific Advisory Board Member |
Joshua Resnick | 49 | 2020 | Independent Director |
Arthur M. Krieg | 66 | - | Scientific Advisory Board Member |
Howard Mayer | 61 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review